| Protocol Number |
Title |
2000LS040
|
MT2000-12 Busulfan, Cyclophosphamide, and Melphalan Followed by Allogeneic Hematopoietic Cell Transplantation in Patients with Hematological Malignancies |
2003NT028
|
COG AALL03B1: Classification of Acute Lymphoblastic Leukemia |
2004CG009
|
COG AALL0232 "HighRisk B-precursor Acute Lymphoblastic Leukemia" |
2004LS006
|
MT2003-15 Use of Cyclophosphamide/Fludarabine to Promote in vivo Expansion of Donor Lymphocyte Infusion s(DLI) to Enhance Efficacy after Allogeneic Transplant |
2005CG018
|
COG ADVL04P2: A Feasibility Pilot and Phase II Study of Chemoimmunotherapy with Epratuzumab (IND#12034) for Children with Relapsed CD22-positive Acute Lymphoblastic Leukemia (ALL) |
2005CG028
|
COG AALL0331: Standard Risk B-Precursor Acute Lymphoblastic Leukemia |
2005LS036
|
MT2005-02: Transplantation of Unrelated Donor Umbilical Cord Blood in Patients with Hematological Malignancies Using a Non-Myeloablative Preparative Regimen |
2005LS075
|
MT2005-25: Hematopoietic Stem Cell Transplantation in the Treatment of Infant Leukemia |
2005NT026
|
AALL03N1 Understanding the Ethnic and Racial Differences in Survival Among Children with Acute Lymphoblastic Leukemia |
2006CG033
|
COG ADVL0413: A Phase I Study of the RAF Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib (BAY 43-9006, NSC# 724772, IND# 69896) in Children with Refractory Solid Tumors or Refractory Leukemias |
2006LS057
|
MT2006-09: Phase I Open Label, Single Arm Escalation Trial to Evaluate the Biodistribution and Safety of BU-12 in Patients with Advanced Leukemia |
2006LS058
|
MT2006-20 CTN 0501 - Multi-center, Open Label, Randomized Trial Comparing Single Versus Double Umbilical Cord Blood (UCB) Transplantation in Pediatric Patients with Leukemia and Myelodysplasia |
2006NT036
|
MT2007-16R Pilot Study of Vascular Function During Hematopoietic Cell Transplantation |
2007CG034
|
COG AALL0434: Intensified Methotrexate, Nelarabine and Augmented BFM Therapy for Children and Young Adults with Newly Diagnosed T-cell Acute Lymphoblastic Leukemia (ALL) |
2007CG045
|
Erwinase Master Treatment Protocol (erwinia asparaginase) |
2007CG058
|
COG AALL0433: Intensive Treatment for Intermediate-Risk Relapse of Childhood B-Precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies |
2007NT102
|
COG AALL05B1: A Children's Oncology Group Protocol for Collecting and Banking Relapsed Acute Lymphoblastic Leukemia Research Samples. |
2008CG050
|
COG AALL07P2 Pharmacology and Toxicity of Erwinia Asparaginase (Erwinase; Cristantaspase; IND 290) Following Allergy to PEG-Asparaginase in Treatment of Children with Acute Lymphoblastic Leukemia (ALL) |
2008CG100
|
COG AALL0631: A Phase III Study of Risk Directed Therapy for Infants with Acute Lymphoblastic Leukemia (ALL): Randomization of Highest Risk Infants to Intensive Chemotherapy +/- FLT3 Inhibition (CEP-701, Lestaurtinib; IND#76431; NSC#617807) |
2008CG164
|
COG ADVL0812 A Phase I Study of MLN8237, an Oral Selective Small Molecule Inhibitor of Aurora A Kinase, in Children with Relapsed/Refractory Solid Tumors and Leukemia |
2008LS112
|
A Therapeutic Trial of Decitabine (Dacogen) and Vorinostat (SAHA) in Combination with Chemotherapy (Vincristine, Prednisone, Doxorubicin and PEG-Asparaginase) for Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL) MT2008-29R |
2009UC052
|
T2005-003: A Study of Bortezomib With Chemotherapy for Relapsed/Refractory Acute Lymphoblastic Leukemia |
Clinical Trials Help